Learning Objectives:
1. Discuss the recent advances and new challenges for developing disease-modifying therapies for monogenic Parkinson's disease
2. Measure the role of Artificial Intelligence (AI) in the daily practice and development of the field of Movement Disorders
3. Discuss the potential positive and negative effects of reducing protein aggregation on neurodegenerative disease progression